CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, multi-national, open-label, 2-arm randomized study in patients with
surgically incurable metastatic melanoma who have received no prior chemotherapy, or
biochemotherapy for the treatment of metastatic disease. The primary objective of this trial
is to compare overall survival for patients with advanced melanoma who are randomized to
receive CP-675,206 with that of patients who are randomized to receive either dacarbazine or
temozolomide (investigator choice)